ClinicalTrials.gg
CompletedNCT02719574Updated Jun 29, 2026Results posted

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

A Phase 1/2 interventional study of FT-2102 (olutasidenib) and Azacitidine in Acute Myeloid Leukemia, Acute Myelogenous Leukemia and Myelodysplastic Syndrome, sponsored by Forma Therapeutics, Inc.. Completed at 60 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Forma Therapeutics, Inc. (part of Novo Nordisk A/S) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
336
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States — 312 open to participants now, 466 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Enrollment
76th of 1,907
336 · median 35
Started
2016
with 88 others
Phase 1/2
306 of 2,137
47 open now
Registered
1,255th of 2,137
by date

Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 76th largest by enrollment of the 1,907 interventional ones that give a count, is one of 89 that started in 2016, is one of 306 in phase 1/2, and was the 1,255th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

312 of the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

307 more — sign in →

All 312 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 (olutasidenib) as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will utilize an open-label design of FT-2102 (olutasidenib) (single agent) and FT-2102 (olutasidenib) + azacitidine (combination agent) administered via one or more intermittent dosing schedules followed by a dose expansion part. The dose expansion part will enroll patients in up to 5 expansion cohorts, exploring single-agent FT-2102 (olutasidenib) activity as well as combination activity with azacitidine or cytarabine. Following the completion of the relevant Phase 1 cohorts, Phase 2 will begin enrollment. Patients will be enrolled across 8 different cohorts, examining the effect of FT-2102 (olutasidenib) (as a single agent) and FT-2102 (olutasidenib) + azacitidine (combination) on various AML/MDS disease states.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndrome

Keywords

  • AML
  • MDS
  • IDH1
  • IDH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven acute myeloid leukemia (AML) (except acute promyelocytic leukemia [APL] with the t(15;17) translocation) or intermediate, high-risk, or very high risk Myelodysplastic Syndrome (MDS) as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R) which is (R/R) to standard therapy and/or for which standard therapy is or which has not adequately responded to standard therapy.
  • Patients must have documented IDH1-R132 gene-mutated disease as evaluated by the site
  • Good performance status
  • Good kidney and liver function

Exclusion criteria

Exclusion Criteria:

  • Patients with symptomatic central nervous system (CNS) or other tumor location (such as spinal cord compression, other compressive mass, uncontrolled painful lesion, bone fracture, etc.) necessitating an urgent therapeutic intervention, palliative care, surgery or radiation therapy
  • Congestive heart failure ( Class III or IV) or unstable angina pectoris. Previous history of myocardial infarction within 1 year prior to study entry, uncontrolled hypertension or uncontrolled arrhythmias
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
336 participants (actual)

Study arms

  • Experimental
    PH1 Dose Escalation & Expansion FT-2102 (olutasidenib)

    Drug: FT-2102 (olutasidenib)

  • Experimental
    PH1 Esc. and Exp. FT-2102 (olutasidenib)+Azacitidine

    Drug: FT-2102 (olutasidenib) · Drug: Azacitidine

  • Experimental
    PH1 Esc. and Exp. FT-2102 (olutasidenib)+Cytarabine

    Drug: FT-2102 (olutasidenib) · Drug: Cytarabine

  • Experimental
    PH2 Cohort 1 FT-2102 (olutasidenib) Single Agent

    Relapsed or Refractory (R/R) AML

    Drug: FT-2102 (olutasidenib)

  • Experimental
    PH2 Cohort 2 FT-2102 (olutasidenib) Single Agent

    AML in morphologic complete remission or complete remission with incomplete blood count recovery (CR/CRi) after prior therapy with residual IDH1-R132 mutation

    Drug: FT-2102 (olutasidenib)

  • Experimental
    PH2 Cohort 3 FT-2102 (olutasidenib) Single Agent

    R/R AML/MDS, previously treated with FT-2102

    Drug: FT-2102 (olutasidenib)

  • Experimental
    PH2 Cohort 4 FT-2102 (olutasidenib)+Azacitidine

    R/R AML/MDS that are naïve to prior hypomethylating therapy and IDH1 inhibitor therapy

    Drug: FT-2102 (olutasidenib) · Drug: Azacitidine

  • Experimental
    PH2 Cohort 5 FT-2102 (olutasidenib)+Azacitidine

    R/R AML/MDS that have inadequately responded to or have progressed on prior hypomethylating therapy

    Drug: FT-2102 (olutasidenib) · Drug: Azacitidine

  • Experimental
    PH2 Cohort 6 FT-2102 (olutasidenib)+Azacitidine

    R/R AML/MDS that have been previously treated with single-agent FT-2102 as their last therapy prior to study enrollment

    Drug: FT-2102 (olutasidenib) · Drug: Azacitidine

  • Experimental
    PH2 Cohort 7 FT-2102 (olutasidenib) Single Agent

    Treatment naïve AML for whom standard treatments are contraindicated

    Drug: FT-2102 (olutasidenib)

  • Experimental
    PH2 Cohort 8 FT-2102 (olutasidenib)+Azacitidine

    Treatment naïve AML who are candidates for azacitidine first line treatment

    Drug: FT-2102 (olutasidenib) · Drug: Azacitidine

Interventions

  • FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level

  • azacitidine will be administered per site's standard of care

    Also known as: Vidaza

  • low-dose cytarabine will be administered per site's standard of care

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    A TEAE was defined as an adverse event (AE) that emerges during treatment, having been absent pre-treatment, or worsens relative to the pre-treatment state. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. Number of participants with TEAEs and SAEs is reported. Safety analysis set (SAS) included all the participants who have received at least one dose of study drug (FT-2102, azacitidine, or cytarabine).

    Time frame: Phase 1: From start of drug administration (Day 1) up to 28 days after last dose of study drug (up to 82 months)

  2. Phase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory Values

    Number of participants with change from baseline in clinically significant abnormal laboratory values for hematology, chemistry and coagulation with Grade \<1 to 4 is reported. National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 toxicity grade used to determine severity of AE. Grade 1: mild;asymptomatic/mild symptoms; Grade 2: moderate; minimal; Grade 3: severe/medically significant; Grade 4: life-threatening consequences, Grade 5: death.

    Time frame: Phase 1: From Baseline up to 28 days after last dose of study drug (up to 82 months)

  3. Phase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Electrocardiogram (ECG)

    Number of participants with change from baseline in clinically significant abnormal ECG parameter (QTcF) is reported. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate.

    Time frame: Phase 1: From Baseline up to 28 days after last dose of study drug (up to 82 months)

  4. Phase 2, Cohort 1: Percentage of Participants With Complete Remission (CR) Plus Complete Remission With Partial Hematological Recovery (CRh) for Acute Myeloid Leukemia Assessed by Investigator Based on International Working Group (IWG) Response Criteria

    Percentage of participants with CR plus CRh (CR, Molecular CR \[CRm\], Cytogenetic CR \[CRc\], CRh) is re-ported. CR is defined as bone marrow blasts less than (\<) 5 percent (%) (in aspirate with spicules and 200 nucleated cells), no blasts with auer rods, no extramedullary disease, absolute neutrophil count (ANC) greater than or equal to (\>=) 1000/μL, platelet count \>=100,000/μL and transfusion independ-ence. CRc is defined as CR with no residual cytogenetic abnormalities. CRm is defined as CR with unde-tectable IDH1m minimal residual disease (MRD) and CRh is defined as bone marrow blasts and partial recovery of peripheral blood counts (platelet count \>50 × 10\^9/L and ANC \> 0.5 × 10\^9/L).

    Time frame: Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)

  5. Phase 2, Cohort 3, 4, 5, 6, 7, 8: Percentage of Participants With CR Plus CRh for Acute Myeloid Leukemia Assessed by Investigator Based on IWG Response Criteria

    Percentage of participants with CR plus CRh (CR, Molecular CR \[CRm\]), Cytogenetic CR \[CRc\], CRh) is re-ported. CR is defined as bone marrow blasts \<5 % (in aspirate with spicules and 200 nucleated cells), no blasts with auer rods, no extramedullary disease, ANC \>=1000/μL, platelet count \>=100,000/μL and transfusion independ-ence. CRc is defined as CR with no residual cytogenetic abnormalities. CRm is de-fined as CR with undetectable IDH1m MRD and CRh is defined as bone marrow blasts and partial recovery of peripheral blood counts (platelet count \>50 × 10\^9/L and ANC \> 0.5 × 10\^9/L).

    Time frame: Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)

  6. Phase 2, Cohort 4 and 5: Percentage of Participants With CR for MDS Assessed by IWG Response Criteria

    Percentage of participants with complete remission (CR) is reported. CR is defined as bone marrow blast ≤ 5% myeloblasts with normal maturation of all cell lines, peripheral blood: Hgb ≥11 grams per deciliter (g/dL), platelets ≥ 100 × 10\^9/L, neutrophils ≥ 1.0 × 10\^9/L and blasts 0%.

    Time frame: Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)

  7. Phase 2, Cohort 2: Four-month Relapse Free Survival (RFS) Rate

    RFS is defined as the time between the date of first dose until relapse or death from any cause, whichever occurs first. RFS is calculated for all participants in Phase 2 Cohort 2. 4-Month RFS rate is defined as the percentage of participants in Phase 2 Cohort 2 who have not relapsed or died on or before their 4-month response evaluation.

    Time frame: Phase 2: From the date of first dose until relapse or death from any cause, whichever occurs first (up to 4 months)

Secondary outcomes

  1. Phase 1: Area Under the Curve (AUClast) for FT-2102

    Area under the plasma concentration-time curve from zero time until the last measurable concentration is presented.

    Time frame: Phase 1: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)

  2. Phase 1: Maximum Plasma Concentration (Cmax) for FT-2102

    Maximum plasma concentration (Cmax) for FT-2102 is presented.

    Time frame: Phase 1: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)

  3. Phase 1: Time to Maximum Plasma Concentration (Tmax) for FT-2102

    Time to reach the maximum plasma concentration (Tmax) is presented.

    Time frame: Phase 1: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)

  4. Phase 1: Time to Response (TTR) for AML

    TTR is the time in months between the first dose of study drug and documentation of the first overall response for participants who achieve a PR or better. This analysis was performed only on participants who have achieved PR or better as a best overall response.

    Time frame: Phase 1: Time from first dose of study drug until documentation of the first overall response (up to 82 months)

  5. Phase 1: Duration of Overall Response for AML

    Duration of response is defined as the time from the date of the first response to the date of the relapse or death. The estimation of median duration of overall response was done by Kaplan-Meier method.

    Time frame: Phase 1: From date of the first response to the date of the relapse or death (up to 82 months)

  6. Phase 1: Time to Response (TTR ) for MDS

    TTR is the time in months between the first dose of study drug and documentation of the first overall response for participants who achieve a PR or better. This analysis was performed only on participants who have achieved PR or better as a best overall response.

    Time frame: Phase 1: Time from first dose of study drug until documentation of the first overall response (up to 82 months)

  7. Phase 2: Time to Response (TTR) for Acute Myeloid Leukemia (AML)

    TTR is the time in months between the first dose of study drug and documentation of the first overall response for participants who achieve a PR or better. This analysis was performed only on participants who have achieved PR or better as a best overall response.

    Time frame: Phase 2: Time from first dose of study drug until documentation of the first overall response (up to 82 months)

  8. Phase 2: Duration of Overall Response for Acute Myeloid Leukemia (AML)

    Duration of overall response is defined as the time from the date of the first response to the date of the relapse or death. The estimation of median duration of overall response was done by Kaplan-Meier method.

    Time frame: Phase 2: From the date of the first response to the date of the relapse or death (up to 82 months)

  9. Phase 2, Cohort 4 and Cohort 5: Time to Response (TTR) for Myelodysplastic Syndrome (MDS)

    TTR is the time in months between the first dose of study drug and documentation of the first overall response for participants who achieve a PR or better. This analysis was performed only on participants who have achieved PR or better as a best overall response.

    Time frame: Phase 2: Time from first dose of study drug until documentation of the first overall response (up to 82 months)

  10. Phase 2, Cohort 4 and Cohort 5: Duration of Overall Response for Myelodysplastic Syndrome (MDS)

    Duration of overall response was calculated similarly to DCR but was assessed the time in months between documentation of the first response of PR or better until the date of relapse, death, whichever is earlier. The estimation of median duration of overall response was done by Kaplan-Meier method. The median duration of overall response is defined as the time at which 50% of the participants in a study have experienced the event of interest (relapse or death). Given the presence of only a single participant in the sample, there is an absence of variability in outcomes, and therefore, it was not possible to ascertain a time point at which half of the participants have experienced the event. Hence, median value could not be calculated.

    Time frame: Phase 2: From the documentation of the first response of PR or better until the date of relapse, death, whichever is earlier (up to 82 months)

  11. Phase 2, Cohort 2: Time to Relapse-Free Survival (RFS)

    RFS was calculated for all participants in Phase 2 Cohort 2. RFS is defined as the time (in months) between the date of first dose until relapse or death from any cause, whichever occurs first. Relapse free survival time to event is reported for all participants in Cohort 2.

    Time frame: Phase 2: From the date of first dose until relapse or death from any cause, whichever occurs first (up to 82 months)

  12. Phase 2: Overall Survival (OS)

    OS is defined as the time in months from the first dose of study drug until death from any cause. For the participants who are not known to have died by the end of study follow-up, OS will be censored on the date the participants was last known to be alive. OS is calculated using Kaplan-Meier method.

    Time frame: Phase 2: From first dose of study drug until death from any cause (up to 82 months)

  13. Phase 2: Event-free Survival (EFS)

    EFS is defined as the time in months between first dose of study drug and disease progression, relapse, death from any cause, treatment failure, or start of other (non-protocol study drug) new antileukemia therapy, whichever occurs first.

    Time frame: Phase 2: From first dose of study drug to disease progression, relapse, death from any cause, treatment failure, or start of other (non-protocol study drug) new antileukemia therapy (up to 82 months)

  14. Phase 2: Transfusion Independence

    Transfusion independence is defined as the number of participants who experience at least a 56-day period during any point on treatment without requiring a transfusion of RBC and/or platelet transfusion. Participants are classified as either "dependent" or "independent" at baseline based on their transfusion history. Those who received either platelets or pRBC or both within 8 weeks prior to the first dose of FT-2102 are considered "dependent". Number of participants with transfusion independent is reported here.

    Time frame: Phase 2: From baseline (8 weeks prior to first dose) up to treatment period (up to 82 months)

  15. Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    A TEAE was defined as an AE that emerges during treatment, having been absent pre-treatment, or worsens relative to the pre-treatment state. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. A SAE is defined as any untoward medical occur-rence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. Number of participants with TEAEs and SAEs is reported.

    Time frame: Phase 2: From start of drug administration (Day 1) up to 28 days after last dose of study drug (up to 82 months)

  16. Phase 2: Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory Values

    Number of participants with change from baseline in clinically significant abnormal laboratory values for hematology, chemistry and coagulation with Grade \<1 to 4 is reported. National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 toxicity grade used to determine severity of AE. Grade 1: mild;asymptomatic/mild symptoms; Grade 2: moderate; minimal; Grade 3: severe/medically significant; Grade 4: life-threatening consequences, Grade 5: death.

    Time frame: Phase 2: From Baseline up to 28 days after last dose of study drug (up to 82 months)

  17. Phase 2: Number of Participants With Change From Baseline in Clinically Significant Abnormal Electrocardiogram (ECG)

    Number of participants with change from baseline in clinically significant abnormal ECG parameter (QTcF) is reported. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate.

    Time frame: Phase 2: From Baseline up to 28 days after last dose of study drug (up to 82 months)

  18. Phase 2: Area Under the Curve (AUClast) for FT-2102

    Area under the plasma concentration-time curve from zero time until the last measurable concentration is presented.

    Time frame: Phase 2: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)

  19. Phase 2: Maximum Plasma Concentration (Cmax) for FT-2102

    Maximum Plasma Concentartion (Cmax) for FT-2102 is presented.

    Time frame: Phase 2: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)

  20. Phase 2: Time to Maximum Plasma Concentration (Tmax) for FT-2102

    Time to reach the maximum plasma concentration (Tmax) for FT-2102 is presented.

    Time frame: Phase 2: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)

07

Results

Posted Jun 26, 2025

Participant flow

Total 336 participants enrolled in the study. In phase I, 78 participants were enrolled in single cohorts (FT-2102) and combination cohorts (FT-2102 with azacitidine/cytarabine) and in phase 2, 258 participants were enrolled in single cohorts (FT-2102) and combination cohorts (FT-2102 with azacitidine).

Phase 1 (Dose Escalation)
Participant flow — Phase 1 (Dose Escalation)
MilestonePhase 1: FT-2102 100mg QD (Single Agent; Dose Escalation)Phase 1: FT-2102 150mg QD (Single Agent; Dose Escalation)Phase 1: FT-2102 150mg BID (Single Agent; Dose Escalation)Phase 1: FT-2102 300mg QD (Single Agent; Dose Escalation)Phase 1: FT-2102 150mg QD+Azacitidine (Combination Therapy; Dose Escalation)Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Escalation)Phase 1: FT-2102 150mg BID (Single Agent; Dose Expansion)Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Expansion)Phase 1: FT-2102 150mg BID+ Cytarabine (Combination Therapy; Dose Expansion)Phase 2: Cohort 1; FT-2102 (Single Agent)Phase 2: Cohort 2; FT-2102 (Single Agent)Phase 2: Cohort 3; FT-2102 (Single Agent)Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 (Single Agent)Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)
Started38747800000000000
Completed00000000000000000
Not completed38747800000000000
Withdrew: Other02122000000000000
Withdrew: Progressive disease13221300000000000
Withdrew: Hsct transplant01202200000000000
Withdrew: Death21100000000000000
Withdrew: Adverse event01001100000000000
Withdrew: Physician decision00001200000000000
Withdrew: Withdrawal by subject00100000000000000
Phase 1 (Dose Expansion)
Participant flow — Phase 1 (Dose Expansion)
MilestonePhase 1: FT-2102 100mg QD (Single Agent; Dose Escalation)Phase 1: FT-2102 150mg QD (Single Agent; Dose Escalation)Phase 1: FT-2102 150mg BID (Single Agent; Dose Escalation)Phase 1: FT-2102 300mg QD (Single Agent; Dose Escalation)Phase 1: FT-2102 150mg QD+Azacitidine (Combination Therapy; Dose Escalation)Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Escalation)Phase 1: FT-2102 150mg BID (Single Agent; Dose Expansion)Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Expansion)Phase 1: FT-2102 150mg BID+ Cytarabine (Combination Therapy; Dose Expansion)Phase 2: Cohort 1; FT-2102 (Single Agent)Phase 2: Cohort 2; FT-2102 (Single Agent)Phase 2: Cohort 3; FT-2102 (Single Agent)Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 (Single Agent)Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)
Started000000931100000000
Completed00000000000000000
Not completed000000931100000000
Withdrew: Progressive disease000000310100000000
Withdrew: Hsct transplant00000015000000000
Withdrew: Death00000016000000000
Withdrew: Adverse event00000021000000000
Withdrew: Physician decision00000012000000000
Withdrew: Other00000017000000000
Phase 2
Participant flow — Phase 2
MilestonePhase 1: FT-2102 100mg QD (Single Agent; Dose Escalation)Phase 1: FT-2102 150mg QD (Single Agent; Dose Escalation)Phase 1: FT-2102 150mg BID (Single Agent; Dose Escalation)Phase 1: FT-2102 300mg QD (Single Agent; Dose Escalation)Phase 1: FT-2102 150mg QD+Azacitidine (Combination Therapy; Dose Escalation)Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Escalation)Phase 1: FT-2102 150mg BID (Single Agent; Dose Expansion)Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Expansion)Phase 1: FT-2102 150mg BID+ Cytarabine (Combination Therapy; Dose Expansion)Phase 2: Cohort 1; FT-2102 (Single Agent)Phase 2: Cohort 2; FT-2102 (Single Agent)Phase 2: Cohort 3; FT-2102 (Single Agent)Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 (Single Agent)Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)
Started0000000001531852021201011
Completed00000000000000000
Not completed0000000001531852021201011
Withdrew: Protocol defined disease progression0000000006582491134
Withdrew: Adverse event000000000270111223
Withdrew: Other000000000207057014
Withdrew: Transplant000000000152061100
Withdrew: Death000000000140011200
Withdrew: Investigator decision00000000061231320
Withdrew: Withdrawal by subject00000000050001120
Withdrew: Protocol violation00000000010000000

Outcome measures

PrimaryPhase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

A TEAE was defined as an adverse event (AE) that emerges during treatment, having been absent pre-treatment, or worsens relative to the pre-treatment state. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. Number of participants with TEAEs and SAEs is reported. Safety analysis set (SAS) included all the participants who have received at least one dose of study drug (FT-2102, azacitidine, or cytarabine).

Time frame:
Phase 1: From start of drug administration (Day 1) up to 28 days after last dose of study drug (up to 82 months)
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPhase 1: FT-2102 (Single Agent)Phase 1: Total FT-2102 (Single Agent)Phase 1: FT-2102 + Azacitidine (Combination Therapy)Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy)
TEAEs16313946
SAEs10233036
PrimaryPhase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory Values

Number of participants with change from baseline in clinically significant abnormal laboratory values for hematology, chemistry and coagulation with Grade \<1 to 4 is reported. National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 toxicity grade used to determine severity of AE. Grade 1: mild;asymptomatic/mild symptoms; Grade 2: moderate; minimal; Grade 3: severe/medically significant; Grade 4: life-threatening consequences, Grade 5: death.

Time frame:
Phase 1: From Baseline up to 28 days after last dose of study drug (up to 82 months)
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory Values
ParticipantsPhase 1: FT-2102 (Single Agent)Phase 1: Total FT-2102 (Single Agent)Phase 1: FT-2102 + Azacitidine (Combination Therapy)Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy)
Hematology: Hemoglobin; Increase(Grade <1)15303845
Hematology: Hemoglobin; Increase (Grade 1)0000
Hematology: Hemoglobin; Increase (Grade 2)0111
Hematology: Hemoglobin; Increase (Grade 3)0000
Hematology: Hemoglobin; Increase (Grade 4)0000
Hematology: Hemoglobin; Increase (Grade 3 or 4)0000
Hematology: Hemoglobin; Decrease (Grade <1)0000
Hematology: Hemoglobin; Decrease (Grade 1)3300
Hematology: Hemoglobin; Decrease (Grade 2)17910
Hematology: Hemoglobin; Decrease (Grade 3)11203036
Hematology: Hemoglobin; Decrease (Grade 4)0000
Hematology: Hemoglobin; Decrease(Grade 3 or 4)11203036
Hematology: Platelets; Decrease (Grade <1)1200
Hematology: Platelets; Decrease (Grade 1)2200
Hematology: Platelets; Decrease (Grade 2)0133
Hematology: Platelets; Decrease (Grade 3)1556
Hematology: Platelets; Decrease (Grade 4)11203137
Hematology: Platelets; Decrease (Grade 3 or 4)12253643
Hematology: Leukocytes; Increase (Grade <1)14283643
Hematology: Leukocytes; Increase (Grade 1)0000
Hematology: Leukocytes; Increase (Grade 2)0000
Hematology: Leukocytes; Increase (Grade 3)1233
Hematology: Leukocytes; Increase (Grade 4)0000
Hematology: Leukocytes; Increase (Grade 3 or 4)1233
Hematology: Leukocytes; Decrease (Grade <1)1212
Hematology: Leukocytes: Decrease (Grade 1)2311
Hematology: Leukocytes; Decrease (Grade 2)1644
Hematology: Leukocytes; Decrease (Grade 3)481416
Hematology: Leukocytes; Decrease (Grade 4)7111923
Hematology: Leukocytes; Decrease (Grade 3 or 4)11193339
Hematology: Neutrophils; Decrease (Grade <1)1111
Hematology: Neutrophils; Decrease (Grade 1)0100
Hematology: Neutrophils; Decrease (Grade 2)0000
Hematology: Neutrophils; Decrease (Grade 3)2522
Hematology: Neutrophils; Decrease (Grade 4)12233643
Hematology: Neutrophils; Decrease (Grade 3 or 4)14283845
Hematology: Lymphocytes; Increase (Grade <1)11192632
Hematology: Lymphocytes; Increase (Grade 1)0000
Hematology: Lymphocytes; Increase (Grade 2)3101112
Hematology: Lymphocytes: Increase (Grade 3)0011
Hematology: Lymphocytes; Increase (Grade 4)0000
Hematology: Lymphocytes; Increase (Grade 3 or 4)0011
Hematology: Lymphocytes; Decrease(Grade <1)1322
Hematology: Lymphocytes; Decrease(Grade 1)2766
Hematology: Lymphocytes; Decrease(Grade 2)561014
Hematology: Lymphocytes; Decrease(Grade 3)5101618
Hematology: Lymphocytes; Decrease(Grade 4)1345
Hematology: Lymphocytes; Decrease(Grade 3 or 4)6132023
Chemistry: Creatinine; Increase (Grade <1)0323
Chemistry: Creatinine; Increase (Grade 1)12232631
Chemistry: Creatinine; Increase (Grade 2)341011
Chemistry: Creatinine; Increase (Grade 3)0011
Chemistry: Creatinine; Increase (Grade 4)0000
Chemistry: Creatinine; Increase (Grade 3 or 4)0011
Chemistry: Calcium; Increase (Grade <1)13283539
Chemistry: Calcium; Increase (Grade 1)0034
Chemistry: Calcium; Increase (Grade 2)0000
Chemistry: Calcium; Increase (Grade 3)1101
Chemistry: Calcium; Increase (Grade 4)1100
Chemistry: Calcium; Increase (Grade 3 or 4)2201
Chemistry: Calcium; Decrease(Grade <1)6121316
Chemistry: Calcium; Decrease(Grade 1)9172326
Chemistry: Calcium; Decrease(Grade 2)0111
Chemistry: Calcium; Decrease(Grade 3)0011
Chemistry: Calcium; Decrease(Grade 4)0000
Chemistry: Calcium; Decrease(Grade 3 or 4)0011
Chemistry: Magnesium; Increase(Grade <1)15283340
Chemistry: Magnesium; Increase(Grade 1)0000
Chemistry: Magnesium; Increase(Grade 2)0000
Chemistry: Magnesium; Increase(Grade 3)0255
Chemistry: Magnesium; Increase(Grade 4)0000
Chemistry: Magnesium; Increase(Grade 3 or 4)0255
Chemistry: Magnesium; Decrease(Grade <1)8172426
Chemistry: Magnesium; Decrease(Grade 1)7131419
Chemistry: Magnesium; Decrease(Grade 2)0000
Chemistry: Magnesium; Decrease(Grade 3)0000
Chemistry: Magnesium; Decrease(Grade 4)0000
Chemistry: Magnesium; Decrease(Grade 3 or 4)0000
Chemistry: Potassium; Increase(Grade <1)13243440
Chemistry: Potassium; Increase(Grade 1)1534
Chemistry: Potassium; Increase(Grade 2)1122
Chemistry: Potassium; Increase(Grade 3)0000
Chemistry: Potassium; Increase(Grade 4)0000
Chemistry: Potassium; Increase(Grade 3 or 4)0000
Chemistry: Potassium; Decrease(Grade <1)10162123
Chemistry: Potassium; Decrease(Grade 1)3101419
Chemistry: Potassium; Decrease(Grade 2)0000
Chemistry: Potassium; Decrease(Grade 3)2444
Chemistry: Potassium; Decrease(Grade 4)0000
Chemistry: Potassium; Decrease (Grade 3 or 4)2444
Chemistry: Sodium; Increase (Grade <1)13273441
Chemistry: Sodium; Increase (Grade 1)2355
Chemistry: Sodium; Increase (Grade 2)0000
Chemistry: Sodium; Increase (Grade 3)0000
Chemistry: Sodium; Increase (Grade 4)0000
Chemistry: Sodium; Increase (Grade 3 or 4)0000
Chemistry: Sodium; Decrease (Grade <1)7151719
Chemistry: Sodium; Decrease (Grade 1)7111924
Chemistry: Sodium; Decrease (Grade 2)0000
Chemistry: Sodium; Decrease (Grade 3)1433
Chemistry: Sodium; Decrease (Grade 4)0000
Chemistry: Sodium; Decrease (Grade 3 or 4)1433
Chemistry: Uric acid; Increase (Grade <1)10212531
Chemistry: Uric acid; Increase (Grade 1)591010
Chemistry: Uric acid; Increase (Grade 2)0000
Chemistry: Uric acid; Increase (Grade 3)0000
Chemistry: Uric acid; Increase (Grade 4)0034
Chemistry: Uric acid; Increase (Grade 3 or 4)0034
Chemistry: Albumin; Decrease(Grade <1)6121416
Chemistry: Albumin; Decrease(Grade 1)5101212
Chemistry: Albumin; Decrease(Grade 2)261216
Chemistry: Albumin; Decrease(Grade 3)2201
Chemistry: Albumin; Decrease(Grade 4)0000
Chemistry: Albumin; Decrease(Grade 3 or 4)2201
Chemistry: Glucose; Increase (Grade <1)13263340
Chemistry: Glucose; Increase (Grade 1)0000
Chemistry: Glucose; Increase (Grade 2)0000
Chemistry: Glucose; Increase (Grade 3)1255
Chemistry: Glucose; Increase (Grade 4)1200
Chemistry: Glucose; Increase (Grade 3 or 4)2455
Chemistry: Glucose; Decrease(Grade <1)14293239
Chemistry: Glucose; Decrease(Grade 1)1155
Chemistry: Glucose; Decrease(Grade 2)0011
Chemistry: Glucose; Decrease(Grade 3)0000
Chemistry: Glucose; Decrease(Grade 4)0000
Chemistry: Glucose; Decrease(Grade 3 or 4)0000
Chemistry: Lipase; Increase (Grade <1)221818
Chemistry: Lipase; Increase (Grade 1)1100
Chemistry: Lipase; Increase (Grade 2)0000
Chemistry: Lipase; Increase (Grade 3)1122
Chemistry: Lipase; Increase (Grade 4)0000
Chemistry: Lipase; Increase (Grade 3 or 4)1122
Chemistry: Amylase; Decrease(Grade <1)451919
Chemistry: Amylase; Decrease(Grade 1)0000
Chemistry: Amylase; Decrease(Grade 2)0000
Chemistry: Amylase; Decrease(Grade 3)0000
Chemistry: Amylase; Decrease(Grade 4)0000
Chemistry: Amylase; Decrease(Grade 3 or 4)0000
Coagulation: Activated partial Thromboplastin Time; Increase(Grade <1)672021
Coagulation: Activated partial Thromboplastin Time; Increase(Grade 1)1122
Coagulation: Activated partial Thromboplastin Time; Increase(Grade 2)0011
Coagulation: Activated partial Thromboplastin Time; Increase(Grade 3)0011
Coagulation: Activated partial Thromboplastin Time; Increase(Grade 4)0000
Coagulation: Activated partial Thromboplastin Time; Increase (Grade 3 or 4)0011
PrimaryPhase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Electrocardiogram (ECG)

Number of participants with change from baseline in clinically significant abnormal ECG parameter (QTcF) is reported. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate.

Time frame:
Phase 1: From Baseline up to 28 days after last dose of study drug (up to 82 months)
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Electrocardiogram (ECG)
ParticipantsPhase 1: FT-2102 (Single Agent)Phase 1: Total FT-2102 (Single Agent)Phase 1: FT-2102 + Azacitidine (Combination Therapy)Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy)
<=450 msec10162326
>450 to <=480 msec4111013
>480 to <=500 msec0212
>500 msec1144
>30 to <=60 msec281314
>60 msec1256
PrimaryPhase 2, Cohort 1: Percentage of Participants With Complete Remission (CR) Plus Complete Remission With Partial Hematological Recovery (CRh) for Acute Myeloid Leukemia Assessed by Investigator Based on International Working Group (IWG) Response Criteria

Percentage of participants with CR plus CRh (CR, Molecular CR \[CRm\], Cytogenetic CR \[CRc\], CRh) is re-ported. CR is defined as bone marrow blasts less than (\<) 5 percent (%) (in aspirate with spicules and 200 nucleated cells), no blasts with auer rods, no extramedullary disease, absolute neutrophil count (ANC) greater than or equal to (\>=) 1000/μL, platelet count \>=100,000/μL and transfusion independ-ence. CRc is defined as CR with no residual cytogenetic abnormalities. CRm is defined as CR with unde-tectable IDH1m minimal residual disease (MRD) and CRh is defined as bone marrow blasts and partial recovery of peripheral blood counts (platelet count \>50 × 10\^9/L and ANC \> 0.5 × 10\^9/L).

Time frame:
Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)
Reported as:
Number · Percentage of participants
Phase 2, Cohort 1: Percentage of Participants With Complete Remission (CR) Plus Complete Remission With Partial Hematological Recovery (CRh) for Acute Myeloid Leukemia Assessed by Investigator Based on International Working Group (IWG) Response Criteria
Percentage of participantsPhase 2: Cohort 1; FT-2102 (Single Agent)
Phase 2, Cohort 1: Percentage of Participants With Complete Remission (CR) Plus Complete Remission With Partial Hematological Recovery (CRh) for Acute Myeloid Leukemia Assessed by Investigator Based on International Working Group (IWG) Response Criteria35 (27.0 to 43.0)
PrimaryPhase 2, Cohort 3, 4, 5, 6, 7, 8: Percentage of Participants With CR Plus CRh for Acute Myeloid Leukemia Assessed by Investigator Based on IWG Response Criteria

Percentage of participants with CR plus CRh (CR, Molecular CR \[CRm\]), Cytogenetic CR \[CRc\], CRh) is re-ported. CR is defined as bone marrow blasts \<5 % (in aspirate with spicules and 200 nucleated cells), no blasts with auer rods, no extramedullary disease, ANC \>=1000/μL, platelet count \>=100,000/μL and transfusion independ-ence. CRc is defined as CR with no residual cytogenetic abnormalities. CRm is de-fined as CR with undetectable IDH1m MRD and CRh is defined as bone marrow blasts and partial recovery of peripheral blood counts (platelet count \>50 × 10\^9/L and ANC \> 0.5 × 10\^9/L).

Time frame:
Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)
Reported as:
Number · Percentage of participants
Phase 2, Cohort 3, 4, 5, 6, 7, 8: Percentage of Participants With CR Plus CRh for Acute Myeloid Leukemia Assessed by Investigator Based on IWG Response Criteria
Percentage of participantsPhase 2: Cohort 3; FT-2102 (Single Agent)Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 (Single Agent)Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)
Phase 2, Cohort 3, 4, 5, 6, 7, 8: Percentage of Participants With CR Plus CRh for Acute Myeloid Leukemia Assessed by Investigator Based on IWG Response Criteria0 (0.0 to 52.2)47 (24.4 to 71.1)38 (13.9 to 68.4)30 (11.9 to 54.3)40 (12.2 to 73.8)45 (16.7 to 76.6)
PrimaryPhase 2, Cohort 4 and 5: Percentage of Participants With CR for MDS Assessed by IWG Response Criteria

Percentage of participants with complete remission (CR) is reported. CR is defined as bone marrow blast ≤ 5% myeloblasts with normal maturation of all cell lines, peripheral blood: Hgb ≥11 grams per deciliter (g/dL), platelets ≥ 100 × 10\^9/L, neutrophils ≥ 1.0 × 10\^9/L and blasts 0%.

Time frame:
Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)
Reported as:
Number · Percentage of participants
Phase 2, Cohort 4 and 5: Percentage of Participants With CR for MDS Assessed by IWG Response Criteria
Percentage of participantsPhase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)
Phase 2, Cohort 4 and 5: Percentage of Participants With CR for MDS Assessed by IWG Response Criteria0 (0.0 to 97.5)13 (0.3 to 52.7)
PrimaryPhase 2, Cohort 2: Four-month Relapse Free Survival (RFS) Rate

RFS is defined as the time between the date of first dose until relapse or death from any cause, whichever occurs first. RFS is calculated for all participants in Phase 2 Cohort 2. 4-Month RFS rate is defined as the percentage of participants in Phase 2 Cohort 2 who have not relapsed or died on or before their 4-month response evaluation.

Time frame:
Phase 2: From the date of first dose until relapse or death from any cause, whichever occurs first (up to 4 months)
Reported as:
Number · Percentage of participants
Phase 2, Cohort 2: Four-month Relapse Free Survival (RFS) Rate
Percentage of participantsPhase 2: Cohort 2; FT-2102 (Single Agent)
Phase 2, Cohort 2: Four-month Relapse Free Survival (RFS) Rate83 (58.6 to 96.4)
SecondaryPhase 1: Area Under the Curve (AUClast) for FT-2102

Area under the plasma concentration-time curve from zero time until the last measurable concentration is presented.

Time frame:
Phase 1: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)
Reported as:
Geometric mean · Hour*nanograms per millilitre (h*ng/mL)
Phase 1: Area Under the Curve (AUClast) for FT-2102
Hour*nanograms per millilitre (h*ng/mL)Phase 1: FT-2102 100 mg QD (Single Agent)Phase 1: FT-2102 150 mg QD (Single Agent)Phase 1: FT-2102 300 mg QD (Single Agent)Phase 1: FT-2102 150 mg BID (Single Agent)Phase 1: FT-2102 150 mg QD+Azacitidine (Combination Therapy)Phase 1: FT-2102 150 mg BID+Azacitidine (Combination Therapy)
Cycle 1 Day 15505 ± 146.98955 ± 63.712100 ± 75.42538 ± 34.28529 ± 51.12288 ± 71.7
Cycle 2 Day 113080 ± 63.514130 ± 124.019140 ± 24.026360 ± 22.37468 ± 92.620640 ± 71.0
SecondaryPhase 1: Maximum Plasma Concentration (Cmax) for FT-2102

Maximum plasma concentration (Cmax) for FT-2102 is presented.

Time frame:
Phase 1: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)
Reported as:
Geometric mean · Nanograms per millilitre (ng/mL)
Phase 1: Maximum Plasma Concentration (Cmax) for FT-2102
Nanograms per millilitre (ng/mL)Phase 1: FT-2102 100 mg QD (Single Agent)Phase 1: FT-2102 150 mg QD (Single Agent)Phase 1: FT-2102 300 mg QD (Single Agent)Phase: FT-2102 150 mg BID (Single Agent)Phase 1: FT-2102 150 mg QD+Azacitidine (Combination Therapy)Phase 1: FT-2102 150 mg BID+Azacitidine (Combination Therapy)
Cycle 1 Day 1571.5 ± 53.1535.0 ± 58.7708.0 ± 58.2495.5 ± 37.4543.3 ± 39.8439.9 ± 56.2
Cycle 2 Day 11913 ± 47.91998 ± 112.92907 ± 36.13703 ± 20.81101 ± 75.43183 ± 51.5
SecondaryPhase 1: Time to Maximum Plasma Concentration (Tmax) for FT-2102

Time to reach the maximum plasma concentration (Tmax) is presented.

Time frame:
Phase 1: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)
Reported as:
Median · hour
Phase 1: Time to Maximum Plasma Concentration (Tmax) for FT-2102
hourPhase 1: FT-2102 100 mg QD (Single Agent)Phase 1: FT-2102 150 mg QD (Single Agent)Phase 1: FT-2102 300 mg QD (Single Agent)Phase 1: FT-2102 150 mg BID (Single Agent)Phase 1: FT-2102 150 mg QD+Azacitidine (Combination Therapy)Phase 1: FT-2102 150 mg BID+Azacitidine (Combination Therapy)
Cycle 1 Day 14.05 (2.22 to 4.12)4.00 (2.02 to 24.00)23.83 (4.00 to 24.00)5.79 (1.00 to 7.83)4.02 (2.00 to 22.55)3.13 (2.03 to 4.12)
Cycle 2 Day 12.23 (2.13 to 4.00)2.00 (1.00 to 2.12)1.00 (0.00 to 1.08)3.00 (0.00 to 7.50)2.29 (2.00 to 4.00)1.18 (0.00 to 2.07)
SecondaryPhase 1: Time to Response (TTR) for AML

TTR is the time in months between the first dose of study drug and documentation of the first overall response for participants who achieve a PR or better. This analysis was performed only on participants who have achieved PR or better as a best overall response.

Time frame:
Phase 1: Time from first dose of study drug until documentation of the first overall response (up to 82 months)
Reported as:
Median · Months
Phase 1: Time to Response (TTR) for AML
MonthsPhase 1: FT-2102 (Single Agent)Phase 1: Total FT-2102 (Single Agent)Phase 1: FT-2102 + Azacitidine (Combination Therapy)Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy)
Phase 1: Time to Response (TTR) for AML1.90 (1.0 to 2.9)1.90 (1.0 to 4.7)1.90 (1.0 to 5.6)1.90 (1.0 to 5.6)
SecondaryPhase 1: Duration of Overall Response for AML

Duration of response is defined as the time from the date of the first response to the date of the relapse or death. The estimation of median duration of overall response was done by Kaplan-Meier method.

Time frame:
Phase 1: From date of the first response to the date of the relapse or death (up to 82 months)
Reported as:
Median · Months
Phase 1: Duration of Overall Response for AML
MonthsPhase 1: FT-2102 (Single Agent)Phase 1: Total FT-2102 (Single Agent)Phase 1: FT-2102 + Azacitidine (Combination Therapy)Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy)
Phase 1: Duration of Overall Response for AML3.60 (1.70 to NA)2.90 (0.90 to 6.40)22.00 (3.20 to NA)22.00 (3.20 to NA)
SecondaryPhase 1: Time to Response (TTR ) for MDS

TTR is the time in months between the first dose of study drug and documentation of the first overall response for participants who achieve a PR or better. This analysis was performed only on participants who have achieved PR or better as a best overall response.

Time frame:
Phase 1: Time from first dose of study drug until documentation of the first overall response (up to 82 months)
Reported as:
Median · Months
Phase 1: Time to Response (TTR ) for MDS
MonthsPhase 1: FT-2102 (Single Agent)Phase 1: Total FT-2102 (Single Agent)Phase 1: FT-2102 + Azacitidine (Combination Therapy)Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy)
Phase 1: Time to Response (TTR ) for MDS4.65 (1.0 to 8.3)4.65 (1.0 to 8.3)2.20 (1.0 to 8.5)2.20 (1.0 to 8.5)
SecondaryPhase 2: Time to Response (TTR) for Acute Myeloid Leukemia (AML)

TTR is the time in months between the first dose of study drug and documentation of the first overall response for participants who achieve a PR or better. This analysis was performed only on participants who have achieved PR or better as a best overall response.

Time frame:
Phase 2: Time from first dose of study drug until documentation of the first overall response (up to 82 months)
Reported as:
Median · Months
Phase 2: Time to Response (TTR) for Acute Myeloid Leukemia (AML)
MonthsPhase 2: Cohort 1; FT-2102 (Single Agent)Phase 2: Cohort 3; FT-2102 (Single Agent)Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 (Single Agent)Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)
Phase 2: Time to Response (TTR) for Acute Myeloid Leukemia (AML)1.90 (0.9 to 10.2)—1.80 (0.9 to 3.8)2.50 (1.0 to 4.2)2.50 (1.0 to 7.6)1.90 (1.8 to 3.9)2.80 (1.1 to 5.6)
SecondaryPhase 2: Duration of Overall Response for Acute Myeloid Leukemia (AML)

Duration of overall response is defined as the time from the date of the first response to the date of the relapse or death. The estimation of median duration of overall response was done by Kaplan-Meier method.

Time frame:
Phase 2: From the date of the first response to the date of the relapse or death (up to 82 months)
Reported as:
Median · Months
Phase 2: Duration of Overall Response for Acute Myeloid Leukemia (AML)
MonthsPhase 2: Cohort 1; FT-2102 (Single Agent)Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 (Single Agent)Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)
Phase 2: Duration of Overall Response for Acute Myeloid Leukemia (AML)14.80 (7.40 to 19.40)20.00 (1.90 to 28.80)7.25 (4.90 to NA)4.65 (2.80 to NA)10.60 (3.5 to 39.6)20.90 (5.60 to NA)
SecondaryPhase 2, Cohort 4 and Cohort 5: Time to Response (TTR) for Myelodysplastic Syndrome (MDS)

TTR is the time in months between the first dose of study drug and documentation of the first overall response for participants who achieve a PR or better. This analysis was performed only on participants who have achieved PR or better as a best overall response.

Time frame:
Phase 2: Time from first dose of study drug until documentation of the first overall response (up to 82 months)
Reported as:
Median · Months
Phase 2, Cohort 4 and Cohort 5: Time to Response (TTR) for Myelodysplastic Syndrome (MDS)
MonthsPhase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)
Phase 2, Cohort 4 and Cohort 5: Time to Response (TTR) for Myelodysplastic Syndrome (MDS)3.30 (3.3 to 3.3)1.50 (1.0 to 13.0)
SecondaryPhase 2, Cohort 4 and Cohort 5: Duration of Overall Response for Myelodysplastic Syndrome (MDS)

Duration of overall response was calculated similarly to DCR but was assessed the time in months between documentation of the first response of PR or better until the date of relapse, death, whichever is earlier. The estimation of median duration of overall response was done by Kaplan-Meier method. The median duration of overall response is defined as the time at which 50% of the participants in a study have experienced the event of interest (relapse or death). Given the presence of only a single participant in the sample, there is an absence of variability in outcomes, and therefore, it was not possible to ascertain a time point at which half of the participants have experienced the event. Hence, median value could not be calculated.

Time frame:
Phase 2: From the documentation of the first response of PR or better until the date of relapse, death, whichever is earlier (up to 82 months)
Reported as:
Median · Months
Phase 2, Cohort 4 and Cohort 5: Duration of Overall Response for Myelodysplastic Syndrome (MDS)
MonthsPhase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)
Phase 2, Cohort 4 and Cohort 5: Duration of Overall Response for Myelodysplastic Syndrome (MDS)NA (NA to NA)11.90 (2.80 to NA)
SecondaryPhase 2, Cohort 2: Time to Relapse-Free Survival (RFS)

RFS was calculated for all participants in Phase 2 Cohort 2. RFS is defined as the time (in months) between the date of first dose until relapse or death from any cause, whichever occurs first. Relapse free survival time to event is reported for all participants in Cohort 2.

Time frame:
Phase 2: From the date of first dose until relapse or death from any cause, whichever occurs first (up to 82 months)
Reported as:
Median · Months
Phase 2, Cohort 2: Time to Relapse-Free Survival (RFS)
MonthsPhase 2: Cohort 2; FT-2102 (Single Agent)
Phase 2, Cohort 2: Time to Relapse-Free Survival (RFS)18.40 (9.50 to NA)
SecondaryPhase 2: Overall Survival (OS)

OS is defined as the time in months from the first dose of study drug until death from any cause. For the participants who are not known to have died by the end of study follow-up, OS will be censored on the date the participants was last known to be alive. OS is calculated using Kaplan-Meier method.

Time frame:
Phase 2: From first dose of study drug until death from any cause (up to 82 months)
Reported as:
Median · Months
Phase 2: Overall Survival (OS)
MonthsPhase 2: Cohort 1; FT-2102 (Single Agent)Phase 2: Cohort 2; FT-2102 (Single Agent)Phase 2: Cohort 3; FT-2102 (Single Agent)Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 (Single Agent)Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)
Phase 2: Overall Survival (OS)11.60 (8.90 to 15.50)NA (27.30 to NA)1.20 (1.10 to NA)25.20 (13.60 to NA)11.60 (5.00 to 27.50)10.20 (4.40 to 17.90)14.00 (1.00 to 19.10)18.70 (1.60 to NA)
SecondaryPhase 2: Event-free Survival (EFS)

EFS is defined as the time in months between first dose of study drug and disease progression, relapse, death from any cause, treatment failure, or start of other (non-protocol study drug) new antileukemia therapy, whichever occurs first.

Time frame:
Phase 2: From first dose of study drug to disease progression, relapse, death from any cause, treatment failure, or start of other (non-protocol study drug) new antileukemia therapy (up to 82 months)
Reported as:
Median · Months
Phase 2: Event-free Survival (EFS)
MonthsPhase 2: Cohort 1; FT-2102 (Single Agent)Phase 2: Cohort 2; FT-2102 (Single Agent)Phase 2: Cohort 3; FT-2102 (Single Agent)Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 (Single Agent)Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)
Phase 2: Event-free Survival (EFS)5.50 (4.30 to 7.40)18.40 (9.50 to NA)1.05 (0.80 to NA)5.70 (1.90 to 16.40)7.80 (2.10 to 10.20)4.80 (2.50 to 9.70)5.50 (0.30 to NA)8.10 (1.60 to 33.00)
SecondaryPhase 2: Transfusion Independence

Transfusion independence is defined as the number of participants who experience at least a 56-day period during any point on treatment without requiring a transfusion of RBC and/or platelet transfusion. Participants are classified as either "dependent" or "independent" at baseline based on their transfusion history. Those who received either platelets or pRBC or both within 8 weeks prior to the first dose of FT-2102 are considered "dependent". Number of participants with transfusion independent is reported here.

Time frame:
Phase 2: From baseline (8 weeks prior to first dose) up to treatment period (up to 82 months)
Reported as:
Count of participants · Participants
Phase 2: Transfusion Independence
ParticipantsPhase 2: Cohort 1; FT-2102 (Single Agent)Phase 2: Cohort 2; FT-2102 (Single Agent)Phase 2: Cohort 3; FT-2102 (Single Agent)Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 (Single Agent)Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)
Phase 2: Transfusion Independence7215012131438
SecondaryPhase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

A TEAE was defined as an AE that emerges during treatment, having been absent pre-treatment, or worsens relative to the pre-treatment state. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. A SAE is defined as any untoward medical occur-rence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. Number of participants with TEAEs and SAEs is reported.

Time frame:
Phase 2: From start of drug administration (Day 1) up to 28 days after last dose of study drug (up to 82 months)
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPhase 2: Cohort 1; FT-2102 (Single Agent)Phase 2: Cohort 2; FT-2102 (Single Agent)Phase 2: Cohort 3; FT-2102 (Single Agent)Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 (Single Agent)Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)
TEAEs1531851921191011
SAEs1156412181389
SecondaryPhase 2: Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory Values

Number of participants with change from baseline in clinically significant abnormal laboratory values for hematology, chemistry and coagulation with Grade \<1 to 4 is reported. National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 toxicity grade used to determine severity of AE. Grade 1: mild;asymptomatic/mild symptoms; Grade 2: moderate; minimal; Grade 3: severe/medically significant; Grade 4: life-threatening consequences, Grade 5: death.

Time frame:
Phase 2: From Baseline up to 28 days after last dose of study drug (up to 82 months)
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory Values
ParticipantsPhase 2: Cohort 1; FT-2102 (Single Agent)Phase 2: Cohort 2; FT-2102 (Single Agent)Phase 2: Cohort 3; FT-2102 (Single Agent)Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 (Single Agent)Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)
Hematology: Hemoglobin; Increase (Grade <1)1461851920201010
Hematology: Hemoglobin; Increase (Grade 1)10001000
Hematology: Hemoglobin; Increase (Grade 2)00000000
Hematology: Hemoglobin; Increase (Grade 3)50000001
Hematology: Hemoglobin; Increase (Grade 4)00000000
Hematology: Hemoglobin; Increase (Grade 3 or 4)50000001
Hematology: Hemoglobin; Decrease (Grade <1)33000100
Hematology: Hemoglobin; Decrease (Grade 1)178010210
Hematology: Hemoglobin; Decrease (Grade 2)463173522
Hematology: Hemoglobin; Decrease (Grade 3)864411181279
Hematology: Hemoglobin; Decrease (Grade 4)00000000
Hematology: Hemoglobin; Decrease (Grade 3 or 4)864411181279
Hematology: Platelets; Decrease (Grade <1)33000010
Hematology: Platelets; Decrease (Grade 1)198010300
Hematology: Platelets; Decrease (Grade 2)143021102
Hematology: Platelets; Decrease (Grade 3)253132523
Hematology: Platelets; Decrease (Grade 4)911413181176
Hematology: Platelets; Decrease (Grade 3 or 4)1164516201699
Hematology: Leukocytes; Increase (Grade <1)1501851820191011
Hematology: Leukocytes; Increase (Grade 1)00000000
Hematology: Leukocytes; Increase (Grade 2)00000000
Hematology: Leukocytes; Increase (Grade 3)20011100
Hematology: Leukocytes; Increase (Grade 4)00000000
Hematology: Leukocytes; Increase (Grade 3 or 4)20011100
Hematology: Leukocytes; Decrease (Grade <1)171202230
Hematology: Leukocytes; Decrease (Grade 1)82001300
Hematology: Leukocytes; Decrease (Grade 2)207030020
Hematology: Leukocytes; Decrease (Grade 3)506146534
Hematology: Leukocytes; Decrease (Grade 4)572212121027
Hematology: Leukocytes; Decrease (Grade 3 or 4)10783161815511
Hematology: Neutrophils; Decrease (Grade <1)12010310
Hematology: Neutrophils; Decrease (Grade 1)21001000
Hematology: Neutrophils; Decrease (Grade 2)65000010
Hematology: Neutrophils; Decrease (Grade 3)214011120
Hematology: Neutrophils; Decrease (Grade 4)11765171915610
Hematology: Neutrophils; Decrease (Grade 3 or 4)138105182016810
Hematology: Lymphocytes; Increase (Grade <1)10317214191488
Hematology: Lymphocytes; Increase (Grade 1)00000000
Hematology: Lymphocytes; Increase (Grade 2)361351421
Hematology: Lymphocytes; Increase (Grade 3)40001000
Hematology: Lymphocytes; Increase (Grade 4)00000000
Hematology: Lymphocytes; Increase (Grade 3 or 4)40001000
Hematology: Lymphocytes; Decrease (Grade <1)182111111
Hematology: Lymphocytes; Decrease (Grade 1)181001410
Hematology: Lymphocytes; Decrease (Grade 2)367074433
Hematology: Lymphocytes; Decrease (Grade 3)4474710645
Hematology: Lymphocytes; Decrease (Grade 4)271045310
Hematology: Lymphocytes; Decrease (Grade 3 or 4)71841115955
Chemistry: Creatinine; Increase (Grade <1)20100010
Chemistry: Creatinine; Increase (Grade 1)9213313101438
Chemistry: Creatinine; Increase (Grade 2)5541510663
Chemistry: Creatinine; Increase (Grade 3)30011000
Chemistry: Creatinine; Increase (Grade 4)01000000
Chemistry: Creatinine; Increase (Grade 3 or 4)31011000
Chemistry: Calcium; Increase (Grade <1)12616414181679
Chemistry: Calcium; Increase (Grade 1)141131312
Chemistry: Calcium; Increase (Grade 2)20001100
Chemistry: Calcium; Increase (Grade 3)00000000
Chemistry: Calcium; Increase (Grade 4)40011000
Chemistry: Calcium; Increase (Grade 3 or 4)40011000
Chemistry: Calcium; Decrease (Grade <1)8313414131646
Chemistry: Calcium; Decrease (Grade 1)504037344
Chemistry: Calcium; Decrease (Grade 2)40001000
Chemistry: Calcium; Decrease (Grade 3)20100100
Chemistry: Calcium; Decrease (Grade 4)70010001
Chemistry: Calcium; Decrease (Grade 3 or 4)90110101
Chemistry: Magnesium; Increase (Grade <1)129183151819910
Chemistry: Magnesium; Increase (Grade 1)130213101
Chemistry: Magnesium; Increase (Grade 2)00000000
Chemistry: Magnesium; Increase (Grade 3)90020010
Chemistry: Magnesium; Increase (Grade 4)00010000
Chemistry: Magnesium; Increase (Grade 3 or 4)90030010
Chemistry: Magnesium; Decrease (Grade <1)10314211171076
Chemistry: Magnesium; Decrease (Grade 1)394384835
Chemistry: Magnesium; Decrease (Grade 2)80000200
Chemistry: Magnesium; Decrease (Grade 3)10000000
Chemistry: Magnesium; Decrease (Grade 4)00000000
Chemistry: Magnesium; Decrease (Grade 3 or 4)10000000
Chemistry: Potassium; Increase (Grade <1)12012517161679
Chemistry: Potassium; Increase (Grade 1)284024232
Chemistry: Potassium; Increase (Grade 2)42001200
Chemistry: Potassium; Increase (Grade 3)00000000
Chemistry: Potassium; Increase (Grade 4)00000000
Chemistry: Potassium; Increase (Grade 3 or 4)00000000
Chemistry: Potassium; Decrease (Grade <1)731417161265
Chemistry: Potassium; Decrease (Grade 1)644384635
Chemistry: Potassium; Decrease (Grade 2)00000000
Chemistry: Potassium; Decrease (Grade 3)90041211
Chemistry: Potassium; Decrease (Grade 4)60100000
Chemistry: Potassium; Decrease (Grade 3 or 4)150141211
Chemistry: Sodium; Increase (Grade <1)13917418192098
Chemistry: Sodium; Increase (Grade 1)130012013
Chemistry: Sodium; Increase (Grade 2)01100000
Chemistry: Sodium; Increase (Grade 3)00000000
Chemistry: Sodium; Increase (Grade 4)00000000
Chemistry: Sodium; Increase (Grade 3 or 4)00000000
Chemistry: Sodium; Decrease (Grade <1)7715313131255
Chemistry: Sodium; Decrease (Grade 1)622258746
Chemistry: Sodium; Decrease (Grade 2)00000000
Chemistry: Sodium; Decrease (Grade 3)120000110
Chemistry: Sodium; Decrease (Grade 4)11010000
Chemistry: Sodium; Decrease (Grade 3 or 4)131010110
Chemistry: Uric acid; Increase (Grade <1)9610511143511
Chemistry: Uric acid; Increase (Grade 1)498065640
Chemistry: Uric acid; Increase (Grade 2)00000000
Chemistry: Uric acid; Increase (Grade 3)00000000
Chemistry: Uric acid; Increase (Grade 4)60011110
Chemistry: Uric acid; Increase (Grade 3 or 4)60011110
Chemistry: Albumin; Decrease (Grade <1)5716078935
Chemistry: Albumin; Decrease (Grade 1)411267622
Chemistry: Albumin; Decrease (Grade 2)451264424
Chemistry: Albumin; Decrease (Grade 3)80102130
Chemistry: Albumin; Decrease (Grade 4)00000000
Chemistry: Albumin; Decrease (Grade 3 or 4)80102130
Chemistry: Glucose; Increase (Grade <1)134185171918910
Chemistry: Glucose; Increase (Grade 1)00000000
Chemistry: Glucose; Increase (Grade 2)00000000
Chemistry: Glucose; Increase (Grade 3)160021211
Chemistry: Glucose; Increase (Grade 4)10000000
Chemistry: Glucose; Increase (Grade 3 or 4)170021211
Chemistry: Glucose; Decrease (Grade <1)1361551718191010
Chemistry: Glucose; Decrease (Grade 1)133010101
Chemistry: Glucose; Decrease (Grade 2)00001000
Chemistry: Glucose; Decrease (Grade 3)00000000
Chemistry: Glucose; Decrease (Grade 4)20011000
Chemistry: Glucose; Decrease (Grade 3 or 4)20011000
Chemistry: Lipase; Increase (Grade <1)1088512161787
Chemistry: Lipase; Increase (Grade 1)134035103
Chemistry: Lipase; Increase (Grade 2)123020110
Chemistry: Lipase; Increase (Grade 3)111000110
Chemistry: Lipase; Increase (Grade 4)10000001
Chemistry: Lipase; Increase (Grade 3 or 4)121000101
Chemistry: Amylase; Decrease (Grade <1)11613513181899
Chemistry: Amylase; Decrease (Grade 1)243032011
Chemistry: Amylase; Decrease (Grade 2)30001000
Chemistry: Amylase; Decrease (Grade 3)40000001
Chemistry: Amylase; Decrease (Grade 4)10000100
Chemistry: Amylase; Decrease (Grade 3 or 4)50000101
Coagulation: Activated partial Thromboplastin Time; Increase (Grade <1)821401313845
Coagulation: Activated partial Thromboplastin Time; Increase (Grade 1)150103203
Coagulation: Activated partial Thromboplastin Time; Increase (Grade 2)10010000
Coagulation: Activated partial Thromboplastin Time; Increase (Grade 3)10000000
Coagulation: Activated partial Thromboplastin Time; Increase (Grade 4)00000000
Coagulation: Activated partial Thromboplastin Time; Increase (Grade 3 or 4)10000000
SecondaryPhase 2: Number of Participants With Change From Baseline in Clinically Significant Abnormal Electrocardiogram (ECG)

Number of participants with change from baseline in clinically significant abnormal ECG parameter (QTcF) is reported. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate.

Time frame:
Phase 2: From Baseline up to 28 days after last dose of study drug (up to 82 months)
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With Change From Baseline in Clinically Significant Abnormal Electrocardiogram (ECG)
ParticipantsPhase 2: Cohort 1; FT-2102 (Single Agent)Phase 2: Cohort 2; FT-2102 (Single Agent)Phase 2: Cohort 3; FT-2102 (Single Agent)Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 (Single Agent)Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)
<=450 msec90111991194
>450 to <=480 msec443367504
>480 to <=500 msec121112111
>500 msec52023302
>30 to <=60 msec433234731
>60 msec100031205
SecondaryPhase 2: Area Under the Curve (AUClast) for FT-2102

Area under the plasma concentration-time curve from zero time until the last measurable concentration is presented.

Time frame:
Phase 2: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)
Reported as:
Geometric mean · h*ng/mL
Phase 2: Area Under the Curve (AUClast) for FT-2102
h*ng/mLPhase 2: Cohort 1; FT-2102 150 mg BID (Single Agent)Phase 2: Cohort 2; FT-2102 150 mg BID (Single Agent)Phase 2: Cohort 3; FT-2102 150 mg BID (Single Agent)Phase 2: Cohort 4; FT-2102 150 mg BID + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 150 mg BID + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 150 mg BID + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 150 mg BID (Single Agent)Phase 2: Cohort 8; FT-2102 150 mg BID + Azacitidine (Combination Therapy)
Cycle 1 Day 12836 ± 59.52657 ± 36.81880 ± 77.43051 ± 109.72031 ± 69.41701 ± 39.44165 ± 116.53898 ± NA
Cycle 2 Day 120610 ± 69.727710 ± 14.9—19820 ± 77.619610 ± 62.121810 ± 45.625880 ± NA19940 ± NA
SecondaryPhase 2: Maximum Plasma Concentration (Cmax) for FT-2102

Maximum Plasma Concentartion (Cmax) for FT-2102 is presented.

Time frame:
Phase 2: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)
Reported as:
Geometric mean · ng/mL
Phase 2: Maximum Plasma Concentration (Cmax) for FT-2102
ng/mLPhase 2: Cohort 1; FT-2102 150 mg BID (Single Agent)Phase 2: Cohort 2; FT-2102 150 mg BID (Single Agent)Phase 2: Cohort 3; FT-2102 150 mg BID (Single Agent)Phase 2: Cohort 4; FT-2102 150 mg BID + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 150 mg BID + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 150 mg BID + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 150 mg BID (Single Agent)Phase 2: Cohort 8; FT-2102 150 mg BID + Azacitidine (Combination Therapy)
Cycle 1 Day 1534.5 ± 57.5492.4 ± 29.3388.8 ± 49.1623.2 ± 75.8404.1 ± 58.5411.2 ± 9.0747.5 ± 107.6671 ± NA
Cycle 2 Day 13136 ± 62.03800 ± 14.7—3239 ± 68.72934 ± 53.63043 ± 39.33500 ± NA3080 ± NA
SecondaryPhase 2: Time to Maximum Plasma Concentration (Tmax) for FT-2102

Time to reach the maximum plasma concentration (Tmax) for FT-2102 is presented.

Time frame:
Phase 2: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)
Reported as:
Median · hour
Phase 2: Time to Maximum Plasma Concentration (Tmax) for FT-2102
hourPhase 2: Cohort 1; FT-2102 150 mg BID (Single Agent)Phase 2: Cohort 2; FT-2102 150 mg BID (Single Agent)Phase 2: Cohort 3; FT-2102 150 mg BID (Single Agent)Phase 2: Cohort 4; FT-2102 150 mg BID + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 150 mg BID + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 150 mg BID + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 150 mg BID (Single Agent)Phase 2: Cohort 8; FT-2102 150 mg BID + Azacitidine (Combination Therapy)
Cycle 1 Day 14.00 (1.00 to 8.00)4.00 (2.00 to 8.00)5.00 (2.00 to 8.00)4.00 (2.00 to 8.00)4.00 (2.00 to 8.00)4.00 (2.00 to 8.00)3.00 (2.00 to 4.00)1.00 (1.00 to 1.00)
Cycle 2 Day 12.00 (0.00 to 8.00)1.00 (0.00 to 2.00)—1.00 (0.00 to 8.00)1.00 (0.00 to 4.00)4.00 (0.00 to 8.00)0.00 (0 to 0)1.00 (1.00 to 1.00)

Adverse events

Collected over From start of drug administration (Day 1) up to 28 days after last dose of study drug (up to 82 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: FT-2102 (Single Agent)4/16 (25%)10/16 (62.5%)15/16 (93.8%)
Phase 1: Total FT-2102 (Single Agent)11/31 (35.5%)23/31 (74.2%)29/31 (93.5%)
Phase 1: FT-2102 + Azacitidine (Combination Therapy)9/39 (23.1%)30/39 (76.9%)39/39 (100%)
Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy)10/46 (21.7%)36/46 (78.3%)46/46 (100%)
Phase 1: Overall21/78 (26.9%)60/78 (76.9%)76/78 (97.4%)
Phase 2: Cohort 1; FT-2102 (Single Agent)50/153 (32.7%)115/153 (75.2%)152/153 (99.3%)
Phase 2: Cohort 2; FT-2102 (Single Agent)0/18 (0%)6/18 (33.3%)18/18 (100%)
Phase 2: Cohort 3; FT-2102 (Single Agent)2/5 (40%)4/5 (80%)5/5 (100%)
Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)3/20 (15%)12/20 (60%)18/20 (90%)
Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)6/21 (28.6%)18/21 (85.7%)20/21 (95.2%)
Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)7/20 (35%)13/20 (65%)19/20 (95%)
Phase 2: Cohort 7; FT-2102 (Single Agent)4/10 (40%)8/10 (80%)10/10 (100%)
Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)2/11 (18.2%)9/11 (81.8%)11/11 (100%)
Most frequent serious events
Showing 10 of 198
Most frequent serious events
EventPhase 1: FT-2102 (Single Agent)Phase 1: Total FT-2102 (Single Agent)Phase 1: FT-2102 + Azacitidine (Combination Therapy)Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy)Phase 1: OverallPhase 2: Cohort 1; FT-2102 (Single Agent)Phase 2: Cohort 2; FT-2102 (Single Agent)Phase 2: Cohort 3; FT-2102 (Single Agent)Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 (Single Agent)Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)
Febrile neutropeniaBlood and lymphatic system disorders3/166/318/3910/4616/7823/1531/182/52/204/212/202/102/11
Disease progressionGeneral disorders0/163/314/395/468/7825/1530/181/53/204/213/201/103/11
PneumoniaInfections and infestations2/167/315/397/4614/7814/1530/181/51/204/212/201/100/11
Acute promyelocytic leukaemia differentiation syndromeRespiratory, thoracic and mediastinal disorders1/162/312/394/466/7814/1530/180/51/202/210/202/100/11
Cerebrovascular accidentNervous system disorders0/160/310/390/460/780/1530/181/50/200/210/200/100/11
Enterococcal bacteraemiaInfections and infestations0/160/310/390/460/780/1530/181/51/200/210/200/100/11
Gastrointestinal haemorrhageGastrointestinal disorders0/160/310/390/460/782/1530/181/50/200/210/200/100/11
Respiratory alkalosisRespiratory, thoracic and mediastinal disorders0/160/310/390/460/780/1530/181/50/200/210/200/100/11
SyncopeNervous system disorders0/160/310/390/460/781/1530/181/50/200/210/200/100/11
Urinary tract infectionInfections and infestations0/161/311/391/462/781/1530/181/51/200/210/201/100/11
Most frequent other events
Showing 10 of 415
Most frequent other events
EventPhase 1: FT-2102 (Single Agent)Phase 1: Total FT-2102 (Single Agent)Phase 1: FT-2102 + Azacitidine (Combination Therapy)Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy)Phase 1: OverallPhase 2: Cohort 1; FT-2102 (Single Agent)Phase 2: Cohort 2; FT-2102 (Single Agent)Phase 2: Cohort 3; FT-2102 (Single Agent)Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 (Single Agent)Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)
NauseaGastrointestinal disorders6/1614/3126/3932/4647/7859/1535/183/511/209/218/202/108/11
ConstipationGastrointestinal disorders4/167/3124/3927/4634/7841/1534/180/55/207/2110/202/107/11
HypokalaemiaMetabolism and nutrition disorders2/167/3113/3916/4623/7833/1531/183/56/201/214/201/104/11
Oedema peripheralGeneral disorders0/161/318/3910/4612/7823/1532/180/53/204/214/205/101/11
VomitingGastrointestinal disorders3/168/3114/3917/4625/7827/1532/180/510/206/216/202/104/11
Platelet count decreasedInvestigations4/168/3118/3920/4628/7831/1533/181/56/209/214/201/103/11
DiarrhoeaGastrointestinal disorders5/167/3116/3921/4629/7831/1531/181/55/207/215/202/104/11
FatigueGeneral disorders6/1613/3116/3919/4632/7835/1536/182/56/206/217/202/100/11
Abdominal painGastrointestinal disorders0/161/317/399/4610/7815/1530/182/52/201/212/202/102/11
Acute promyelocytic leukaemia differentiation syndromeRespiratory, thoracic and mediastinal disorders2/162/314/394/466/7811/1530/182/52/200/210/200/101/11

Baseline characteristics

Full Analysis Set (FAS) included all the participants who were enrolled in the study and have received at least one dose of FT-2102.

Age, Customized
Age, Customized(Participants)Phase 1: FT-2102 100mg QD (Single Agent; Dose Escalation)Phase 1: FT-2102 150mg QD (Single Agent; Dose Escalation)Phase 1: FT-2102 150mg BID (Single Agent; Dose Escalation)Phase 1: FT-2102 300mg QD (Single Agent; Dose Escalation)Phase 1: FT-2102 150mg QD+Azacitidine (Combination Therapy; Dose Escalation)Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Escalation)Phase 1: FT-2102 150mg BID (Single Agent; Dose Expansion)Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Expansion)Phase 1: FT-2102 150mg BID+ Cytarabine (Combination Therapy; Dose Expansion)Phase 2: Cohort 1; FT-2102 (Single Agent)Phase 2: Cohort 2; FT-2102 (Single Agent)Phase 2: Cohort 3; FT-2102 (Single Agent)Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 (Single Agent)Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)Total
<65 years0313510100375116330189
65 - <75 years03401561406811329936144
>=75 years322112371482129874103
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: FT-2102 100mg QD (Single Agent; Dose Escalation)Phase 1: FT-2102 150mg QD (Single Agent; Dose Escalation)Phase 1: FT-2102 150mg BID (Single Agent; Dose Escalation)Phase 1: FT-2102 300mg QD (Single Agent; Dose Escalation)Phase 1: FT-2102 150mg QD+Azacitidine (Combination Therapy; Dose Escalation)Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Escalation)Phase 1: FT-2102 150mg BID (Single Agent; Dose Expansion)Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Expansion)Phase 1: FT-2102 150mg BID+ Cytarabine (Combination Therapy; Dose Expansion)Phase 2: Cohort 1; FT-2102 (Single Agent)Phase 2: Cohort 2; FT-2102 (Single Agent)Phase 2: Cohort 3; FT-2102 (Single Agent)Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 (Single Agent)Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)Total
Female252255514074621171062158
Male1352234171791239141049178
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1: FT-2102 100mg QD (Single Agent; Dose Escalation)Phase 1: FT-2102 150mg QD (Single Agent; Dose Escalation)Phase 1: FT-2102 150mg BID (Single Agent; Dose Escalation)Phase 1: FT-2102 300mg QD (Single Agent; Dose Escalation)Phase 1: FT-2102 150mg QD+Azacitidine (Combination Therapy; Dose Escalation)Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Escalation)Phase 1: FT-2102 150mg BID (Single Agent; Dose Expansion)Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Expansion)Phase 1: FT-2102 150mg BID+ Cytarabine (Combination Therapy; Dose Expansion)Phase 2: Cohort 1; FT-2102 (Single Agent)Phase 2: Cohort 2; FT-2102 (Single Agent)Phase 2: Cohort 3; FT-2102 (Single Agent)Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)Phase 2: Cohort 7; FT-2102 (Single Agent)Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)Total
American Indian or Alaska Native000000000000000000
Asian0001000205101000010
Native Hawaiian or Other Pacific Islander000000000000000000
Black or African American0201001305010200015
White35726681917110411141356191
More than one race01001000016000100221
Unknown or Not Reported00000207056708475399
08

Study locations

60 sites
  • UCLA Medical Center
    Los Angeles, California 90024, United States
  • UC Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
  • Yale University
    New Haven, Connecticut 06510, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Emory Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • University of Maryland Greenebaum Cancer Center
    Baltimore, Maryland 21201, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • New York Medical College
    Hawthorne, New York 10532, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Cornell University Weill Medical College
    New York, New York 10065, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Oregon Health & Science University
    Portland, Oregon 97229, United States
  • Sarah Cannon Research Institute - Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Victoria Cancer Care Center
    Parkville, Victoria 3000, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • Box Hill Hospital, Monash University and Eastern Health Clinical School
    Box Hill, 3128, Australia
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • Service d'Hématologie Clinique, Hôpital Avicenne-APHP-Université Paris
    Bobigny, 93000, France
  • Assistance Publique Hopitaux de Marseille (AP-HM) - Hopital Nord
    Marseille, 13005, France
  • Centre Hospitalier Universitaire Nantes
    Nantes, 44093, France
  • Hôpital Saint-Louis
    Paris, 75010, France
  • Hopitaux Universitaires Est Parisien Hopital Saint-Antoine
    Paris, 75012, France
  • Centre Hospitalier Universitaire (CHU) Bordeaux - Hospitaux du Haut Leveque
    Pessac, 33604, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, 69495, France
  • University Hospital of Rennes
    Rennes, 35033, France
  • Institut Universitaire du Cancer Toulouse - Oncopole
    Toulouse, 31059, France
  • Centre Hospitalier Universitaire de Nancy - Hopital Brabois
    Vandœuvre-lès-Nancy, 54511, France
  • Institut de Cancérologie Gustave Roussy
    Villejuif, 94805, France
  • Staedtisches Klinikum Braunschweig gGmbH
    Braunschweig, Germany
  • Universitaetsklinikum Giessen und Marburg GmbH - Klinik fuer Innere Medizin
    Giessen, Germany
  • Landeszentrum fuer Zell- und Gentherapie
    Halle, Germany
  • Universitätsklinikum Münster Medizinische Klinik A, Hämatologie, Hämostaseologi
    Münster, Germany
  • AOU S. Luigi Gonzaga - Orbassano
    Orbassano, Turin, Italy
  • Ospedale Mazzoni - UOC Ematologia Ascoli Piceno
    Ascoli Piceno, Italy
  • Universita di Bologna
    Bologna, Italy
  • Dipartimento di Oncologia Medica - IRST IRCC
    Meldola, Italy
  • Università degli Studi di Parma
    Parma, Italy
  • U.O. Ematologia Ravenna
    Ravenna, Italy
  • Hospital Rimini Hematology, Department of Oncology and Hematoloy
    Rimini, Italy
  • Seoul National University Bundang Hospital
    Gumi, 13620, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Hospital Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 8036, Spain
  • Institut Català d'Oncologia-Hospital Duran i Reynals
    Barcelona, 8908, Spain
  • Hospital Universitario 12 De Octubre
    Madrid, 28041, Spain
  • Hospital Clínico Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital La Fe
    Valencia, 46026, Spain
  • University College London Hospitals NHS Foundation Trust
    London, NW1 2PG, United Kingdom
  • St. George's University Hospital
    London, United Kingdom
  • Churchill Hospital
    Oxford, United Kingdom
  • Southampton General Hospital
    Southampton, United Kingdom
  • Royal Marsden Hospital
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Cortes J, Curti A, Fenaux P, Jonas BA, Krauter J, Montesinos P, Recher C, Taussig DC, Wang ES, Watts J, Wei A, Yee KW, Tian H, Sheppard A, Marzac C, de Botton S. Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort. J Hematol Oncol. 2025 Nov 14;18(1):102. doi: 10.1186/s13045-025-01751-w. PubMed 41239466 ↗
  • Cortes JE, Yang J, Roboz GJ, Dinner SN, Wang ES, Wei AH, Tian H, di Trapani F, Baer MR, Donnellan W, Watts JM. Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome. Blood Adv. 2025 Oct 28;9(20):5293-5305. doi: 10.1182/bloodadvances.2025016718. PubMed 40668616 ↗
  • Cortes JE, Roboz GJ, Baer MR, Jonas BA, Schiller GJ, Yee K, Ferrell PB, Yang J, Wang ES, Blum WG, Mims A, Tian H, Sheppard A, de Botton S, Montesinos P, Curti A, Watts JM; Olutasidenib Combination Therapy Study Group. Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial. J Hematol Oncol. 2025 Jan 16;18(1):7. doi: 10.1186/s13045-024-01657-z. PubMed 39819505 ↗
  • de Botton S, Fenaux P, Yee K, Recher C, Wei AH, Montesinos P, Taussig DC, Pigneux A, Braun T, Curti A, Grove C, Jonas BA, Khwaja A, Legrand O, Peterlin P, Arnan M, Blum W, Cilloni D, Hiwase DK, Jurcic JG, Krauter J, Thomas X, Watts JM, Yang J, Polyanskaya O, Brevard J, Sweeney J, Barrett E, Cortes J. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 2023 Jul 11;7(13):3117-3127. doi: 10.1182/bloodadvances.2022009411. PubMed 36724515 ↗
  • Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, Recher C, Jonas BA, Ferrell PB Jr, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2023 Jan;10(1):e46-e58. doi: 10.1016/S2352-3026(22)00292-7. Epub 2022 Nov 10. PubMed 36370742 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Dec 2023, 91 months.

Results were first posted in Jun 2025, 1 year 5 months after primary completion.

Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's 91 months is above that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2016
First posted
Mar 25, 2016
StartActual
Apr 30, 2016
Primary completionActual
Dec 28, 2023
CompletionActual
Jan 24, 2024
Results first posted
Jun 26, 2025
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02719574
Responsible party
Sponsor
First posted
Mar 25, 2016
Start date
Apr 30, 2016
Primary completion
Dec 28, 2023
Completion
Jan 24, 2024
Results posted
Jun 26, 2025
Last update
Jun 29, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olutasidenib

Start the discussion